Financials

  • Market Capitalization 400.55 M
  • Employee 45
  • Founded 2019
  • CEO N/A
  • Website www.x4pharma.com
  • Headquarter Delaware, United States
  • FIGI BBG001J1CYH8
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
3.68
ratio cours/chiffre d'affaires
35.88

Related tickers

#NomPrix24h %7 jours %1M %1 an %Cap Boursière7 Derniers Jours
3065
LRMR
Larimar Therapeutics, Inc. - Common Stock
3.82 USD-4.74%-6.37%-0.26%+4.37%396.83 M USD
3068
GALT
Galectin Therapeutics Inc. - Common Stock
3.95 USD-1.74%+1.02%+33.00%-7.71%398.36 M USD
3105
EYPT
EyePoint, Inc. - Common Stock
4.50 USD+0.45%-9.64%-63.53%-62.50%387.95 M USD
3111
ENTA
Enanta Pharmaceuticals, Inc. - Common Stock
13.30 USD-2.21%-5.67%+4.72%+52.87%387.37 M USD

Nouvelles